Greg Rustowicz
Analyst · D.A. Davidson. Please proceed
Thank you, David. Good morning, everyone. On slide seven, net sales in the second quarter were $231.7 million, up 8.5% from the prior year period on a constant currency basis and within the guidance we provided last quarter. Delayed shipments resulting from supply chain challenges continued at a similar pace to last quarter and impacted sales by approximately $20 million -- $26 million in the second quarter. Looking at our sales bridge, pricing was a major driver of our growth, up $11 million or 4.9%. This amount was up 40 basis points from our Q1 level. Our specialty conveying platform continues to deliver strong performance, with the Garvey acquisition providing $9 million of growth. Overall volume declined slightly by 0.4% or $900,000, which was largely the result of material shortages that I previously mentioned. Foreign currency translation reduced sales by $11 million or 4.9% of sales. Let me provide a little color on sales by region. For the second quarter, the 6.9% growth we saw in the U.S. was driven by a 5.8% improvement in pricing. As you are aware, we increased prices in both March and June this year. Acquired revenue added 4.5% growth. This more than offset a 3.4% decline in sales volume. Outside of the U.S., sales grew 7.5%, excluding FX and the acquisition. Pricing improved by 3.7% and sales volume increased by 3.8%. We were encouraged with the volume increases we saw, which were approximately 1% each in Europe and Canada and 36% in Latin America. The growth in Latin America reflects the region’s lagging post-pandemic recovery, as well as specific growth initiatives that are showing traction. APAC volume was flat due to the various lockdowns that have occurred in that region of the world. On slide eight, gross margin of 37.2% was up 90 basis points from the prior year. On an adjusted basis, gross margin was higher by 50 basis points, driven by the Garvey acquisition, which was 50 basis points accretive to our adjusted gross margin this quarter. Let me point out a few highlights on our gross profit bridge. Second quarter gross profit increased $5.2 million compared with the prior year and was driven by several factors. The Garvey acquisition provided $4.5 million of gross profit and $9 million of revenue, equating to a 50% gross margin. Pricing net of material inflation added $4.4 million of gross profit, demonstrating our pricing power. Offsetting these items was foreign currency translation, which reduced gross profit by $4.1 million, reflecting the strong U.S. dollar compared to the euro. Moving to slide nine, our SG&A or our operating expenses were $52.5 million in the quarter or 22.7% of sales. This included $1.2 million of business realignment costs, as we advance our new commercial structure. Sequentially, operating expenses were lower than Q1 by $700,000 due to the benefits of our business realignment and FX translation. Compared to the prior year, our SG&A costs were higher by $1.3 million with the acquisition adding $1.2 million. We also incurred $900,000 of incremental business realignment costs related to our commercial reorganization. We invested an incremental $1.6 million in R&D costs and our annual merit increases became effective July 1st. Offsetting these increases were about $1 million in savings from the commercial realignment and foreign currency translation, which reduced our cost by $2.3 million. For the fiscal third quarter, we expect our SG&A expense to approximate $54 million. Turning to slide 10, we achieved record operating income in the quarter of $27.4 million and adjusted operating income of $28.6 million. Operating income benefited from the acquisition and our pricing power, which more than offset the negative impact of foreign currency translation that reduced operating income by $1.6 million. Adjusted operating margin was 12.4% of sales, 100 basis point increase over the prior year and up 130 basis points from the trailing quarter. We realized strong operating leverage in the quarter of 38.6%. As you can see on slide 11, we recorded GAAP earnings per diluted share for the quarter of $0.49. Our tax rate on a GAAP basis was 26% in the quarter. For the full year, the tax rate is expected to be between 29% and 31%, which reflects a 6 percentage point impact from the two discrete items that we discussed last quarter. Adjusted earnings per diluted share of $0.73 was down $0.01 from the prior year. Impacting EPS was higher interest expense, as well as FX losses and mark-to-market investment losses, which together impacted EPS by $0.10 per share year-over-year. Even though we are 60% hedged to interest rate exposure, interest expense is expected to increase to $7.2 million in the third quarter. FX and investment losses are also expected to continue in the third quarter as well. We estimate these combined headwinds will impact pretax earnings by $1 million. Weighted average diluted shares outstanding will approximate $29 million and our pro forma tax rate is 22% for calculating non-GAAP adjusted earnings per share. On slide 12, our adjusted EBITDA margin for the quarter was a record 16.8% and our trailing 12-month EBITDA margin increased to 15.6%. The Garvey acquisition was accretive to our adjusted EBITDA margin in the quarter by 80 basis points. Our trailing 12-month return on invested capital improved to 6.9%. We are making progress towards our targets of $1.5 billion in revenue with a 21% EBITDA margin as covered at our recent Investor Day. Moving to slide 13, we had positive free cash flow of $15 million in the second quarter. This includes cash inflows from operating activities of $17 million and CapEx of $2 million. We anticipate that our free cash flow will continue to build through the course of the fiscal year as we drive earnings and reduce working capital as a percent of sales back to the mid-teen levels. We now expect full year capital expenditures to be in a range of $12 million to $15 million, down from previous guidance due to the timing of projects. Turning to slide 14, we have a strong and flexible capital structure comprised of a term loan B, which requires $5.3 million of required principal payments annually and has an excess cash flow sweep depending on our total leverage. We paid down $20 million of debt year-to-date and expect to pay $40 million for the entire fiscal year. The term loan B is 60% hedged with interest rate swaps that blend to a swap rate of approximately 2.08%. As of September 30, on a pro forma basis, which includes Garvey’s LTM adjusted EBITDA, but excludes expected cost synergies, our net leverage ratio was 2.8 times. We are prioritizing debt repayment in the current environment. Finally, our liquidity, which includes our cash on hand and revolver availability, remained strong and was approximately $173 million at the end of September. Please advance to slide 15 and I will turn it back over to David.